1. Comparison with traditional antioxidants
Martin Brand is a famous professor exploring free radical production in aging and disease. In one lecture, he told us that most antioxidants remove Reactive oxygen species (ROS) too late, like mopping up spilled red wine from white carpet. In comparison, Elixiria’s compound target specific site of mitochondria, like a cork in a specific wine bottle, prevent overproduction of these reactive species more not only in in the right time and right site, and thus provide more precise and thorough neuroprotection.
2. Comparison with PPAR gamma agonists
Our ELB00824 is the most the BBB permeable PPAR gamma agonists in the world, and thus may has improved therapeutic window.
3. Comparison with other neuropathic painkillers
There are four major processes: transduction, transmission, modulation, and perception. ELB00824 target the first step. Most painkillers target one or more ion channels in the latter step. However, there are 215 ion channels that exist in the human genome, with 85 ion channels that are linked to pain (strong literature linking them to pain). As an analogy, imagine if you have 85 holes in your roof. You can’t just plug one or even half of the holes and expect the problem to resolve. If there is a bath shower above the roof, why not just turn off the shower. That is how our compound works. It targets the upstream contributor (e.g., mitochondria), but not the downstream mediators in the pain pathway. Each has failed in one pain clinical trial.
However, many venture capitals and public funds still focus on symptomatic treatment by modulation of ion channel signaling, and disregard the dying nerve, the real source of the pain. Many channel blockers (e.g., a voltage-gated T-type calcium channel), have no real pain-attenuating actions, or if they did have, it has been difficult to design molecules that can block just one channel (e.g., Nav1.7) and not closely related ion channels that play critical roles outside pain sensing. After 2018, a slate of drug developers have reported failures in trials testing ion channel inhibitors for pain management, calling into question the promise of the class of analgesics.